Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 1

Navigating mCRC: Treatment Options in the Third-Line Setting

November 21, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.

Now Viewing

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

What is your typical preferred treatment option when treating patients in the third-line setting? What are some currently available options?
Please focus on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib.
Please share your overall experience with these current therapies and which is the best fit depending on the type of patient or clinical scenario.
I’m interested in hearing your clinical perspective…what patient or disease-specific factors do you consider when choosing from these currently available regimens?